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Supplementary Note 1 
 
In addition to exogenous TGF-b3 stimulation, endogenous signaling from other members of the 
TGF-b superfamily (e.g., bone morphogenetic proteins (BMPs), growth and differentiation 
factors (GDFs)) is also essential for regulating chondrogenesis. To investigate how C59 
treatment alters gene expression profiles of these families and their associated receptors 
(including Type I and Type II receptors), we used CCA to align chondrocytes populations and 
mesenchymal cells from d14 pellets with or without C59 treatment. We also observed that C59 
treatment decreased BMP2, BMP4, BMP6, and BMP7 gene expression, but it increased GDF5 
and GDF10 gene expression. For receptors, C59 treatment enhanced expression levels of 
BMPR1B and ACVR1, but it decreased BMPR2, ACVR2A, and ACVR2B expression 
(Supplementary Fig. 11A-B and 12A-B). BMP8A, BMP10, BMP11, and BMP15, as well as 
GDF2, GDF4, GDF6, and GDF8 were not detected in our datasets. 
To investigate how C59 treatment affects the percentage of cells expressing genes of 
interest within a specific chondrocyte subpopulation, we used BMP4, GDF5, BMPR1B (type I 
receptor), and BMPR2 (type II receptor) as examples (Supplementary Fig. 10B-E). For BMP4, 
C59-treated pellets had a decreased percentage of BMP4-expressing cells within all 
chondrocyte subpopulations except ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes as 
compared to pellets treated with TGF-b3 only condition. In addition, C59-treated pellets also 
demonstrated a remarkably increased percentage of GDF5 and BMPR1B expressing cells 
within all chondrocyte populations versus TGF-b3-treated pellets. Furthermore, C59 decreased 
the percentage of the cells expressing BMPR2 in LECT1/EPYC/FRZB+ early-mature, 
ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes, BNIP3/FAM162+ chondrocytes, and 
HMGB2/CDK1+ and UBE2C/CCNB1+ proliferating chondrocytes. Interestingly, it appeared that 
C59 treatment did not significantly affect the contribution of a chondrocyte subpopulation to the 
cells expressing a given gene (i.e., the cells expressing the genes of interests mainly came from 
LECT1/EPYC/FRZB+ early-mature chondrocytes regardless of the treatments as presented in 





Supplementary Figure 1. Step-wise differentiation of hiPSCs toward chondrocytes via 
specification of mesoderm 
(A) Differentiation protocol of hiPSCs into chondrocytes.  
(B) Cell morphology at each stage during mesodermal differentiation. Please note that low cell density at 
hiPSC stage is required to obtain successful mesodermal differentiation. Scale bar = 500 µm. 




Supplementary Figure 2. GO enrichment analysis of bulk RNA-seq data and subcutaneous 
implantation of hiPSC-derived chondrocytes in mice 
(A) GO enrichment analysis of bulk RNA-seq data showing that up-regulated genes were involved in 
skeletal system and cartilage development.  
(B) d14 chondrogenic pellets maintained a cartilage phenotype indicated by intense Saf-O and COL2A1 
staining after 14 days of subcutaneous implantation in mice. n = 3 mice.  
(C) The off-target cells (mostly located at the edge of perichondrium, yellow arrowheads) were observed 
in the pellets derived from 3 distinct hiPSC lines.  




Supplementary Figure 3. Analysis of scRNA-seq data reveals diverse cell populations in hiPSC-
derived chondrogenic pellets  
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(A) scRNA-seq of mixed specie samples showing low multiplet rates (< 2.7%).     
(B) CCA of scRNA-seq data from d28 chondrogenic pellets from 2 independent experiments (i.e., 2 
batches). 8 conserved cell clusters were identified in both batches.    
(C) Cells in the same cluster from different batches exhibited high correlation in their gene expression 
(Spearman’s rank coefficient rs > 0.87 for all clusters). 
(D) Cells in the clusters from distinct batches demonstrated similar gene expression patterns. 
(E) Additional neural cell markers such as DCX, MAP2, OTX1, and PAX6 were also enriched in the 
branch of neurogenic differentiation. 
(F) SOX4+ and SOX4/SOX9+ cells at the Cp stage had high expression of neural crest cell markers. A 
total of 1,888 cells at the Cp stage that passed quality control was analyzed. 
(G) Cells that are enriched for PRRX1, COL1A1, COL3A1, and COL5A1 were annotated as 
“mesenchyme” at the Cp stage. A total of 1,888 cells at the Cp stage that passed quality control was 
analyzed. 
(H) Three major cell populations observed in d3 pellets. A total of 2,485 cells from d3 pellets that passed 
quality control was used to generate the tSNE plot. 
(I) Fraction of major cell types over the course of differentiation (Cp – d28). A total of 11,208 cells from the 
Cp stage to d28 pellets was analyzed.  
(J) IHC against nestin and MITF confirms the presence of neural cells and melanocytes in pellets. 
(K) Mesenchymal cells in d14 pellets expressed several conventionally recognized MSC markers. 
However, whether these mesenchymal cells exhibit multipotency like MSCs requires further investigation. 




Supplementary Figure 4. WGCNA reconstructed GRNs of neurogenesis and melanogenesis and 
identified the hub genes in each network  
 8 
(A-B) GRNs of neurogenesis and melanogenesis. Topological analysis (community cluster) was 
performed to visualize subnetworks.   
(C) WNT4 was among the hub genes in the GRN of neurogenesis while WNT2B was associated with the 
GRN of melanocyte development.  
(D-F) Representative d28 pellet images showing that C59 or a combination of C59 and ML treatment 
during pellet culture enhanced the homogeneity of chondrogenesis by removing off-target cells. This was 
validated in 3 unique hiPSC lines.   
(G) The pellets treated with C59 or a combination of C59 and ML treatment exhibited significantly 
increased GAG/DNA ratios compared to the pellets treated with ML and the pellets treated TGF-b3. * C59 
vs. TGF-b3 (p = 0.01) at a specific timepoint.  # C59 + ML vs. TGF-b3 (p = 0.001) at a specific timepoint.  
Mean ± SEM. n = 4 pellets per treatment condition. One-way ANOVA with Fisher’s LSD was performed at 
d28 and d42.  
(H) hMSCs harvested from 3 distinct donors exhibited increased chondrogenesis when treated with C59 
during pellet culture.  
(I) hMSCs harvested from donor 1 and donor 3 had significantly increased GAG/DNA ratios when treated 
with C59 compared to with TGF-b3 alone. # C59 vs. TGF-b3 (p = 0.01) at specific time point. Mean ± 





Supplementary Figure 5. Semi-quantification of RNA-FISH against WNTs and COL2A1. 
C59-treated pellets showed decreased WNT3A and WNT4 expression but increased COL2A1 RNA-FISH 




Supplementary Figure 6. Multiple CCA alignment of d7-d42 pellets reveals that 4 conserved 
chondrocyte subpopulations and 1 conserved mesenchymal population were observed in C59-
treated pellets  
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(A) Jitter plots showing that C59-treated pellets had increased expression of ACAN, COL2A1, and SOX9 
but decreased SOX2 versus Standard TGF-b3-treated pellets  
(B) Temporal expression profiles of signature genes of each chondrocyte subpopulation. CDK1 and 
IGFBP5 showed transient upregulation while COL9A1 and COL11A1 remained up-regulated once 
activated. MMP13 and MX1 showed increased expression levels at later time points. 
(C) Dynamic changes in the percentage of the cell population within the pellets over the course of 
differentiation.  
(D) ISG15/IFI6/MX1+ chondrocytes contained 4.6% cells expressing both VEGFA and MMP13 
(E-F) BMPR1B/ITGA4+ progenitors previously identified in articular cartilage were mostly observed in 
HMGB2/CDK1+ proliferating chondrocytes. 
(G) LECT1/EPYC/FRZB+ early-mature chondrocytes had the highest levels of COL2A1 and ACAN 
expression among other chondrocyte subpopulations. 
(H) ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes expressed several IFN-related genes.  
(I) In comparison with IGFBP5+ early chondrocytes, ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes 
showed high expression in IGFBP3 but decreased expression in FOS.  
(J) The expression of various hypertrophic chondrocyte markers.  
For scRNA-seq analysis of C59 treated pellets, total 7,997 cells (from d7-d42) passed quality control and 
thus were analyzed for this figure. 





Supplementary Figure 7. ACTA2/PRRX1/COL1A1+ mesenchymal cells in the pellets, but not 
mesenchymal cells at the Cp stage, exhibit similar gene expression profile to perichondrial cells.  
(A) ACTA2/PRRX1/COL1A1+ mesenchymal cells in the pellets expressed markers of rat perichondrial 
cells.  
(B) ACTA2/PRRX1/COL1A1+ mesenchymal cells from d7 and d14 pellets were enriched with 8 of 15 
differentially expressed genes in the perichondrium-like membrane of the human chondrogenic pellet.  
Particularly, d7 ACTA2/PRRX1/COL1A1+ mesenchymal cells had the highest expression of C2orf91, 
FGF18, GGT7, CHST9, and ZNH354C. Interestingly, we also observed that there was gradual shift in the 
gene expression profile of ACTA2/PRRX1/COL1A1+ mesenchymal cells from d28 to d42. For example, 
d28 ACTA2/PRRX1/COL1A1+ mesenchymal cells were enriched in NRN1 and CH3L1 while d42 cells 




Supplementary Figure 8. The GRN of hiPSC chondrogenesis  
(A) The GRN and hub genes of hiPSC chondrogenesis. 
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(B) CCA was used to identify DEGs of each subpopulation between d14 pellets with and without C59 
treatment. ID2, a neurogenic marker (blue circle), was decreased in proliferative cells in C59-treated 
pellets, while PRG4 (red circle) was increased in mesenchymal cells in C59-treated pellets. 
(C) CCA alignment of cells from d28 pellets with and without C59 treatment. A total of 3,027 cells from 
d28 pellets with and without C59 treatment was used to performed CCA alignment.  
(D) CCA was used to identify DEGs of chondrocytes between d28 pellets with and without C59 treatment. 
Markers for mature-hypertrophic chondroocytes, such as IFI6 and ISG15 (blue circles), were decreased 
while ACAN and COMP (red circles) were increased in C59-treated pellets. 
(E) Similar to the WNT expression profiles in d14 pellets, most WNTs were expressed by proliferative 




Supplementary Figure 9.   
(A) Schematic of WNT treatment during chondrogenic pellet culture. 
(B) RT-qPCR of d14 pellets treated various WNTs showing that gene expression of WNTs can be 
modulated by other WNT ligands. Different letters are significantly different from each other (p < 0.05). 
Mean ± SEM. n = 3-4 pellets per group. Statistical significance was determined by one-way ANOVA with 
Tukey’s post-hoc test. 
(C) Semi-quantification of Saf-O and IHC labeling against various collagens. 
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(D) Percentage of the cells expressing a variety of WNTs in d14 pellets treated with TGF-b3. For scRNA-




Supplementary Figure 10. Differential expression of BMPs/GDFs and receptors in response to 
WNT inhibition  
(A) CCA alignment of chondrocyte and mesenchymal populations from TGF-b3 only and C59 conditions.  
 18 
(B) C59-treated pellets had a decreased percentage of BMP4 expressing cells within all clusters except 
within ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes. 
(C and D) C59-treated pellets demonstrated a remarkably increased percentage of GDF5 and BMPR1B 
expressing cells within all clusters versus TGF-b3-treated pellets.  
(E) C59 treatment decreased percentage of cells expressing BMPR2 in LECT1/EPYC/FRZB+ early-
mature chondrocytes, ISG15/IFI6/MX1+ mature-hypertrophic chondrocytes, BJIP3/FAM162+ apoptotic 
chondrocytes, as well as HMGB2/CDK1+ and UBE2C/CCNB1/KPNA2+ proliferating chondrocytes. 
(B-E) Note that C59 treatment did not significantly affect the contribution of a cluster to the cells expressing 
BMP4, GDF5, BMPR1B, and BMPR2 as presented in the pie charts. 
For bioinformatic analysis, CCA was performed with a total of 1,335 cells from mesenchymal and 
chondrocyte populations from d14 TGF-b3 pellets and with a total of 3,047 cells from mesenchymal and 








Supplementary Figure 11.  CCA analysis showing differential gene expression with C59 treatment. 
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(A) BMP and (B) GDF families in chondrocyte subpopulations due to C59 treatment. Numerical value on 
top of each bar in the bar graph indicates cell numbers expressing a given gene. For bioinformatic 
analysis, CCA was performed with a total of 1,335 cells from mesenchymal and chondrocyte populations 
from d14 TGF-b3 pellets and with a total of 3,047 cells from mesenchymal and chondrocyte populations 






Supplementary Figure 12.  CCA analysis showing differential receptor gene expression with C59 
treatment.  
(A) Type I and (B) type II receptors for the BMP/GDF family in chondrocyte subpopulations due to C59 
treatment. Numerical value on top of each bar in the bar graph indicates cell numbers expressing a given 
gene. For bioinformatic analysis, total 2,148 cells from d14 TGF-b3 treated pellets and total 3,076 cells 
from d14 C59+TGF-b3 treated pellets passed quality control and thus were analyzed for this figure.  
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Supplementary Table 1.  Related to Figure 1. Top 10 up-regulated genes in fold change in 
mesodermal phase   
Ensembl Symbol AP vs hiPSC PM vs AP ES vs Par Scl vs ES ES vs Cp 
ENSG00000113722 CDX1 7.47 1.28 -5.77 -1.90 -2.03 
ENSG00000185155 MIXL1 7.32 -2.67 -4.09 -2.29 0.91 
ENSG00000222033 LINC01124 7.32 0.31 -5.65 -2.48 2.72 
ENSG00000164458 T 7.19 -0.13 -5.22 -2.84 -1.81 
ENSG00000104371 DKK4 7.13 -2.61 -5.28 -0.92 1.07 
ENSG00000274981  6.99 -0.44 -4.38 -2.01 -0.10 
ENSG00000241345 LOC105375483 6.80 1.09 -5.53 -1.25 2.06 
ENSG00000253308  6.75 2.33 -7.08 -1.82 2.23 
ENSG00000106038 EVX1 6.51 0.01 -5.38 -2.44 1.48 
ENSG00000105991 HOXA1 6.34 3.87 -2.36 -1.99 -1.85 
ENSG00000049249 TNFRSF9 1.16 6.93 -5.79 -0.95 3.01 
ENSG00000120094 HOXB1 2.25 6.54 -3.53 -3.39 -0.37 
ENSG00000151379 MSGN1 3.11 6.23 -5.27 -3.42 -0.60 
ENSG00000137252 HCRTR2 0.01 6.01 -2.13 -0.74 1.57 
ENSG00000179111 HES7 0.97 5.54 -2.97 -2.34 -0.34 
ENSG00000253552  2.07 5.13 0.68 -2.19 -0.52 
ENSG00000182742 HOXB4 1.54 4.93 1.00 -1.24 -0.41 
ENSG00000129654 FOXJ1 -2.73 4.73 -2.53 1.02 1.48 
ENSG00000163083 INHBB -2.68 4.55 -0.68 -2.63 1.58 
ENSG00000100678 SLC8A3 -0.89 4.53 -0.27 -0.63 -1.42 
ENSG00000147223 RIPPLY1 -0.02 -0.99 11.49 -8.93 -1.53 
ENSG00000005102 MEOX1 0.06 0.37 9.05 -1.35 -5.05 
ENSG00000164853 UNCX -1.66 0.00 8.92 -0.59 -1.21 
ENSG00000136698 CFC1 -2.67 2.82 8.33 -4.80 -1.36 
ENSG00000224865 LOC101928782 0.07 0.01 8.17 -2.92 -4.34 
ENSG00000168269 FOXI1 1.00 -0.91 8.12 -4.89 -3.26 
ENSG00000102837 OLFM4 0.99 -0.16 7.77 -4.75 -0.94 
ENSG00000176692 FOXC2 0.89 0.83 7.24 -1.11 -2.23 
ENSG00000176678 FOXL1 -0.32 0.94 7.15 -2.86 -1.48 
ENSG00000213931 HBE1 1.07 0.33 7.12 -1.58 -0.82 
ENSG00000136327 NKX2-8 2.46 -0.32 -2.04 9.99 -3.90 
ENSG00000184302 SIX6 0.22 -1.31 -3.65 8.29 -0.28 
ENSG00000008196 TFAP2B 2.42 0.63 -4.51 7.30 1.47 
ENSG00000274021  -0.86 0.85 -6.19 6.97 -1.09 
ENSG00000064218 DMRT3 0.99 0.80 -2.70 6.97 -3.17 
ENSG00000139318 DUSP6 -0.39 0.72 -6.78 6.96 -1.03 
ENSG00000176165 FOXG1 0.14 0.67 -0.64 6.81 -3.11 
ENSG00000244405 ETV5 -0.05 0.62 -6.23 6.76 -1.15 
ENSG00000152785 BMP3 -0.82 0.49 0.16 6.63 -3.57 
ENSG00000178235 SLITRK1 -0.99 0.33 -2.34 6.62 -2.86 
ENSG00000180828 BHLHE22 2.88 -1.47 -2.00 -3.08 7.73 
ENSG00000167941 SOST -1.11 0.36 5.37 -4.87 7.09 
ENSG00000188620 HMX3 -2.25 -0.08 2.35 -3.91 6.47 
ENSG00000164125 FAM198B 0.87 -0.59 -0.25 1.80 6.30 
ENSG00000163132 MSX1 4.90 0.75 -2.60 -1.44 6.30 
ENSG00000175899 A2M -0.10 -0.72 -0.41 1.55 6.29 
ENSG00000165092 ALDH1A1 -0.27 -1.01 -1.47 0.82 6.20 
ENSG00000109846 CRYAB -1.24 -0.25 -0.09 -0.25 6.12 
ENSG00000107984 DKK1 5.15 -0.85 -3.78 -2.19 6.10 
ENSG00000122641 INHBA -1.45 -1.94 1.50 -0.96 6.07 
 
AP: anterior primitive streak; PM: paraxial mesoderm; ES: early somite, Scl: Sclerotome; Cp: Chondroprogenitor  
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Supplementary Table 2. Related to Figure 1. Top 10 up-regulated genes in fold change in 
chondrogenic phase   
 
  
Ensembl Symbol d7 vs Cp d14 vs d7 d21 vs d14 d28 vs d21 d42 vs d28 
ENSG00000124159 MATN4 7.69 1.22 0.73 -1.28 -0.68 
ENSG00000181195 PENK 7.65 1.16 -0.23 -0.15 -0.51 
ENSG00000008441 NFIX 7.08 -0.36 1.15 -0.69 0.43 
ENSG00000006611 USH1C 7.01 -0.34 -0.37 -0.64 0.73 
ENSG00000157554 ERG 6.44 -0.47 -0.45 -0.25 -0.51 
ENSG00000171812 COL8A2 6.19 -0.01 0.68 -1.48 0.21 
ENSG00000124134 KCNS1 6.18 0.48 0.42 -0.68 -1.88 
ENSG00000121898 CPXM2 5.87 0.80 1.01 -0.05 0.52 
ENSG00000224765  5.75 -0.37 0.53 -0.83 -0.15 
ENSG00000145708 CRHBP 5.66 -2.59 0.34 0.56 -3.25 
ENSG00000249945  -2.48 5.07 -4.36 -0.50 0.13 
ENSG00000135480 KRT7 -2.54 4.98 1.00 -0.08 -0.17 
ENSG00000278530 CHMP1B2P -0.11 4.80 -4.40 -1.15 -1.39 
ENSG00000234787 LINC00458 -2.38 4.34 -2.06 0.93 -0.91 
ENSG00000182798 MAGEB17 -3.16 4.24 -1.13 -1.02 2.03 
ENSG00000278840  -2.23 4.19 0.70 -0.59 0.73 
ENSG00000253507  -0.90 4.00 -2.28 -0.13 0.48 
ENSG00000187569 DPPA3 0.15 3.96 -1.73 0.95 -0.79 
ENSG00000196767 POU3F4 2.51 3.94 -1.98 -0.60 -2.49 
ENSG00000101842 VSIG1 -1.03 3.81 -1.35 -0.37 2.15 
ENSG00000011083 SLC6A7 -0.34 -1.09 6.22 -1.47 -0.62 
ENSG00000205890 LOC100128770 -2.25 1.60 5.78 -3.33 -1.20 
ENSG00000152213 ARL11 -1.54 -1.42 5.10 -4.03 1.23 
ENSG00000233841 HLA-C -0.97 0.94 5.06 -5.06 1.81 
ENSG00000117091 CD48 0.74 -0.73 4.77 -3.40 -1.04 
ENSG00000166869 CHP2 -3.55 0.82 4.70 -4.51 1.21 
ENSG00000204121  -3.93 1.36 4.51 -3.57 1.80 
ENSG00000224865 LOC101928782 0.13 -0.54 4.48 -4.29 2.13 
ENSG00000182912  -0.87 -1.29 4.45 -2.86 0.11 
ENSG00000188257 PLA2G2A 2.84 -1.28 4.22 1.86 -0.02 
ENSG00000213931 HBE1 -3.49 1.31 -0.55 3.12 -4.81 
ENSG00000207927 MIR302A -0.72 0.80 -1.84 2.87 0.72 
ENSG00000120094 HOXB1 -0.17 1.40 -1.90 2.82 -3.71 
ENSG00000164746 C7orf57 -0.30 -0.16 -0.92 2.77 -0.75 
ENSG00000183463 URAD -2.49 -0.82 0.69 2.68 -3.05 
ENSG00000203635  -0.46 0.86 -2.09 2.66 -1.49 
ENSG00000131095 GFAP 0.18 0.65 1.11 2.65 0.93 
ENSG00000255282 WTAPP1 -2.90 -1.23 0.75 2.62 -0.60 
ENSG00000101276 SLC52A3 -1.43 1.12 -1.39 2.57 -0.83 
ENSG00000277060 NLRP2 -1.14 1.39 -1.19 2.56 -2.86 
ENSG00000166828 SCNN1G -2.23 0.06 -0.22 0.46 4.32 
ENSG00000129451 KLK10 -2.31 -0.66 1.84 0.73 3.96 
ENSG00000168447 SCNN1B -1.71 0.49 3.90 -3.56 3.84 
ENSG00000176654  -1.05 2.23 1.68 -4.23 3.50 
ENSG00000234745 HLA-B 0.48 -0.20 0.68 -1.09 3.48 
ENSG00000013588 GPRC5A 0.83 -0.05 1.38 0.16 3.45 
ENSG00000105392 CRX 0.14 1.54 -1.45 -1.03 3.32 
ENSG00000137265 IRF4 -1.02 -0.43 3.20 -1.55 3.27 
ENSG00000123689 G0S2 -2.25 0.07 1.75 0.99 3.25 
ENSG00000161652 IZUMO2 -1.81 -1.56 0.78 0.27 3.02 
 24 
Supplementary Table 3. Key resources  
 
REAGENT or 
RESOURCE SOURCE IDENTIFIER 
Antibodies 
COL1A1 Abcam Cat#90395 
COL2A1 Iowa Hybridoma Bank Cat#II-II6B3-s 
COL6A1 Fitzgerald Industries Cat#70F-CR009X 
COL10A1 Sigma Cat#C7974 
Goat Anti-Mouse Abcam Cat#97021 
Goat Anti-Rabbit Abcam Cat#6720 
Probe- Hs-WNT3A Advanced Cell Diagnostics Cat#429431 
Probe- Hs-COL2A1 Advanced Cell Diagnostics Cat#427871 
Probe- Hs-WNT4 Advanced Cell Diagnostics Cat#429441 
Anti-Nestin antibody Abcam Cat#ab105389 
Anti-Wnt2B  Abcam Cat#ab178418 
Anti-Wnt5B Abcam Cat#ab93134 
Anti-Wnt3A Abcam Cat#ab81614 
Anti-Wnt4 Abcam Cat#ab91226 
Anti-Wnt7B Abcam Cat#b155313 
FITC-CD45 Biolegend Cat#304006 
PE/Cy7-CD146 Biolegend Cat#361008 
PE-CD166 Biolegend Cat#343904 
Tru Stain FC XTM Biolegend Cat#422302 
DAPI Biolegend Cat#422801 
Chemicals, Peptides, and Recombinant Proteins 
Activin R&D Systems Cat#338-AC 
CHIR99021 Stemgent Cat#04-0004 
FGF2 R&D Systems Cat#233-FB-025/CF 
Dorsomorphin Stemgent Cat#04-0024 
BMP4 R&D Systems Cat#314-BP-010/CF 
Wnt-C59   Cellagen Technology Cat#C7641-2s 
ML329 Axon Medchem CAT#HY-101464 
SB-505124 Tocris Cat#3263 
PD173074  Tocris Cat#3044 
Purmorphamine Stemgent Cat#04-0009 




Advanced Cell Diagnostics Cat#320850 
RNAscope® Wash 
Buffer Reagents Advanced Cell Diagnostics Cat#310091 
Vitronectin Thermo Fisher Scientific Cat#A31804 
ReLeSR STEMCELL Technologies Cat#05872 
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Collagenase, Type 2 Worthington Biochemical Cat#LS004177 
Papain Sigma–Aldrich Cat#P4762 
Human BMP-4 R&D Systems Cat#314-BP-01M  
Human WNT-4 R&D Systems Cat#6076-WN-005 
Human WNT-3A R&D Systems Cat#5036-WN-010 
Mouse WNT-2B R&D Systems Cat#3900-WN-025 
Human WNT-5B  R&D Systems Cat#7347-WN-025 
Human WNT7B Abcam Cat#ab152805 
Essential 8 Flex 
medium Thermo Fisher Scientific Cat#A2858501 
CellMatrix Basement 
Membrane ATCC Cat#ACS3035 
Pluripotent Stem Cell 
SFM XF/FF medium ATCC Cat#ACS3002 
ReLeSR STEMCELL Technologies Cat#05872 
DMEM-low glucose Thermo Fisher Scientific Cat#11885092 
Penicillin/streptomycin Thermo Fisher Scientific Cat#15140-122 
Fetal bovine serum Atlanta Biologicals Cat#S11550 
Fibroblast growth factor R&D Systems Cat#233-FB 
Ham's F-12  Thermo Fisher Scientific Cat#31765092 
 
IMDM Thermo Fisher Scientific Cat#31980097 
 
DMEM/F-12,  Thermo Fisher Scientific Cat#10565042 
Y-27632 STEMCELL Technologies Cat#72304 
chemically defined lipid 
concentrates 
Gibco Cat#11905031 
ITS+ Corning Cat#354352 
1-thioglycerol Sigma–Aldrich Cat#M6145 
TrypLE Gibco Cat#12604013 
b-mercaptoethanol Thermo Fisher Scientific Cat#21985023 
dexamethasone Sigma–Aldrich Cat#D4902 
L-proline Sigma–Aldrich Cat#P5607 
L-ascorbic acid Sigma–Aldrich Cat#A8960 
NEAA Gibco Cat#11140050 
Critical Commercial Assays 
Total RNA Purification 
Kit  Norgen Biotek Cat#37500 
Ribo-Zero Gold rRNA 




Single Cell 30 Library 
and Gel Bead Kit V2  10x Genomics Cat#120237 
Chromium single cell 
chip kit V2 10x Genomics Cat#120236 
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Agilent High Sensitivity 
DNA Kit  Agilent Cat#5067-4626 
Quant-iT PicoGreen 
dsDNA Assya Kit  Thermo Fisher Scientific Cat#P11496 
Software and Algorithms 
R v3.5  R project https://www.r-project.org 
Cell Ranger v3 10x Genomics https://support.10xgenomics.com/ 
DESeq2 (Love et al., 2014)47 https://bioconductor.org/packages/release/bioc/html/DESeq2.html 
Seurat v2.4 (Butler et al., 2018)15 https://satijalab.org/seurat/ 
Monocle2  (Qiu et al., 2017)62 https://github.com/cole-trapnell-lab/monocle-release 




Circlize (Gu et al., 2014)48 https://github.com/jokergoo/circlize 
Cytoscape 3.6.1  (Shannon et al., 2003)49 https://www.cytoscape.org/ 
ComplexHeatmap 
 





PolysorbTM, suture Covidien Cat#L-2800 
Micro bone drill Roboz Cat#RS-6300A 
Epinephrine 1:1000 International Medication Systems Cat#491590 




Supplementary Table 4. Subject details 
 
Donor ID Study ID Cell type GenoType Age, Sex Characterization 
PHBI-BA-060 STAN iPSC wt/wt 1 yr, M Ref8 
SCRC-1041 ATCC iPSC wt/wt Newborn, M Ref48 
BJFF.6 BJFF iPSC wt/wt Newborn, M Ref49 
hMSC3 Donor 1 MSC wt/wt 51, F This study 
hMSC4 Donor 2 MSC wt/wt 38, M This study 





Supplementary Table 5. Numbers of the cells passed quality control (QC) for each stage 











     
Monolayer culture 
 
hiPSC 6258 4798 1688 1651 
Sclerotome 2237 1861 3107 2240 
Cp 2536 1888 3443 1754 
Sum 11031 8547 8238 5645 
Average 3677 2849 2746 1882 
     
TGF-b3 chondrogenic pellets 
 
d1 2418 2216 3447 2097 
d3 2810 2485 3357 1835 
d7 1369 1200 4049 2302 
d14 2266 2148 3784 2001 
d28 1321 1271 2900 2178 
d42 1355 1328 2324 1955 
Sum 11539 10648 19861 12368 
Average 1923 1775 3310 2061 
     
TGF-b3 + C59 chondrogenic pellets 
 
d7 2191 1682 4030 1733 
d14 3461 3076 2718 1693 
d28 1881 1756 2714 1991 
d42 1926 1483 3003 2126 
Sum 9459 7997 12456 7543 
Average 2365 1999 3116 1886 
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Supplementary Table 6: qRT-PCR Primer Sequences. Primers are listed as 5’ to 3’.  
 
Gene Forward Sequence Reverse Sequence 
ACAN CACTTCTGAGTTCGTGGAGG ACTGGACTCAAAAAGCTGGG 
COL1A1 TGTTCAGCTTTGTGGACCTC TTCTGTACGCAGGTGATTGG 
COL2A1 GGCAATAGCAGGTTCACGTA CTCGATAACAGTCTTGCCCC 
COL10A1 CATAAAAGGCCCACTACCCAAC ACCTTGCTCTCCTCTTACTGC 
MITF AGTTGCTGGCGTAGCAAGAT AAAGTCAACCGCTGAAGAGC 
PAX6 GAGTGCCCGTCCATCTTTG GTCTGCGCCCATCTGTTGCTTTTC 
SOX2 TACAGCATGATGCAGGACCA CCGTTCATGTAGGTCTGCGA 
SOX9 CGTCAACGGCTCCAGCAAGAACAA GCCGCTTCTCGCTCTCGTTCAGAAGT 
TBP AACCACGGCACTGATTTTCA ACAGCTCCCCACCATATTCT 
WNT2B GTGTCCTGGCTGGTTCCTTA AGCTGGTGCAAAGGAAAGAA 
WNT3A CCTGCACTCCATCCAGCTACA GACCTCTCTTCCTACCTTTCCCTTA 
WNT4 GATGTGCGGGAGAGAAGCAA ATTCCACCCGCATGTGTGT 
WNT5B CTGCCTTTCCAGCGAGAATT AGGTCAAATGGCCCCCTTT 
WNT7B CCCCCTCCCTGGATCATGCACA GCCACCACGGATGACAGTGCT 
